Azodicarbonamide

Drug Profile

Azodicarbonamide

Alternative Names: ADA; HPH-116; NSC 674447

Latest Information Update: 17 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Universite Libre de Bruxelles
  • Developer H-Phar; Universite Libre de Bruxelles
  • Class Amides; Aza compounds; Small molecules
  • Mechanism of Action HIV zinc finger inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections
  • No development reported Transplant rejection

Most Recent Events

  • 17 Aug 2015 Phase-II development is ongoing in Spain for HIV infections
  • 30 Aug 2011 Azodicarbonamide is still in phase II trials for HIV infection in Spain
  • 05 Sep 2007 Phase-II clinical trials in HIV infections treatment in Spain (Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top